Cheryl Hillery, MD, clinical director of Hematology in the Division of Pediatric Hematology/Oncology, was invited to be part of the NIH NHLBI Clinical Trials Review Committee.
Edward Prochownik, MD, PhD, Division of Pediatric Hematology/Oncology, published two manuscripts dealing witih drug development in the journal OncoTarget. OncoTarget’s mission is to make scientific results rapidly and widely available and to foster applications of basic and clinical science to fight disease. Dr. Prochownik published 12 manuscripts in 2014-15.
- Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion.
- Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Mark Vander Lugt, MD, of the Division of Blood and Marrow Transplantation and Cellular Therapies, has developed a biorepository to collect and store samples from patients with primary immunodeficiencies and malignancies and who are undergoing hematopoietic stem cell transplant. The goal is to bank samples for future research in order to better understand the complex processes underlying these diseases.